Minerva Neurosciences reported $0 in Loan Capital for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Acadia Pharmaceuticals ACAD:US $ 0M 0M
Adma Biologics ADMA:US $ 138.42M 43.56M
ALKERMES ALKS:US 292.17M 633K
AstraZeneca AZN:LN 28805M 83M
Biocryst Pharmaceuticals BCRX:US $ 604.46M 19M
Bristol Myers Squibb BMY:US $ 37450M 2155M
Dynavax Technologies DVAX:US $ 220.76M 0.27M
Eli Lilly And LLY:US $ 15152.9M 193.5M
Esperion Therapeutics ESPR:US $ 258.68M 398K
GlaxoSmithKline GSK:LN 29226M 8654M
Halozyme Therapeutics HALO:US $ 788.1M 0.84M
IONIS PHARMACEUT IONS:US $ 1247.93M 19.91M
Johnson & Johnson JNJ:US $ 28851M 1134M
Marinus Pharmaceuticals MRNS:US $ 69.93M 29.12M
Merk MRK:US $ 30586M 104M
Minerva Neurosciences NERV:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 377.7M 42.6M
Novartis NOVN:VX SF 24373M 150M
Novavax NVAX:US $ 0M 323.46M
Pfizer PFE:US $ 35656M 539M
Takeda 4502:JP Y 4141418M 90521M
Vanda Pharmaceuticals VNDA:US $ 0M 0M